2023-12-22T10:02:06-06:00 2023-06-30 451135289 BD & COMPANY INC 11155 RED RUN BLVD STE 410 OWINGS MILLS MD 21117 990 2022-07-01 263690883 THE LIEBER INSTITUTE INC LIEB 4109551000 855 N WOLFE ST 3RD FL BALTIMORE MD 21205 ANDREW MASLAN CFO 4109551000 2023-12-22 1 ANDREW MASLAN 999009999 0 DOUGLAS RUSSENBERGER P01338068 4104159700 2023-12-22 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z ANDREW MASLAN 855 N WOLFE ST 3RD FL BALTIMORE MD 21205 47405363 0 X LIBD.ORG X 2008 MD THE MISSION OF THE INSTITUTE IS TO TRANSLATE BASIC GENETIC AND MOLECULAR MECHANISMS OF SCHIZOPHRENIA AND RELATED DEVELOPMENTAL BRAIN DISORDERS INTO CLINICAL ADVANCES THAT CHANGE THE LIVES OF AFFECTED INDIVIDUALS. IT IS CATALYZING A NEW UNDERSTANDING OF BRAIN DISEASE BY LINKING ADVANCES IN THE CONSTRUCTION AND FUNCTION OF THE HUMAN BRAIN WITH THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES. 10 9 152 9 0 0 16080378 26098672 2921001 1749804 3134968 700573 757875 354066 22894222 28903115 0 0 0 0 15511810 16987100 0 0 0 14001188 14461830 29512998 31448930 -6618776 -2545815 31106210 36656603 5801214 12690938 25304996 23965665 X THE MISSION OF THE INSTITUTE IS TO TRANSLATE BASIC GENETIC AND MOLECULAR MECHANISMS OF SCHIZOPHRENIA AND RELATED DEVELOPMENTAL BRAIN DISORDERS INTO CLINICAL ADVANCES THAT CHANGE THE LIVES OF AFFECTED INDIVIDUALS. IT IS CATALYZING A NEW UNDERSTANDING OF BRAIN DISEASE BY LINKING ADVANCES IN THE CONSTRUCTION AND FUNCTION OF THE HUMAN BRAIN WITH THE DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES. 0 0 4645870 223498 CLINICAL SCIENCES: THE CLINICAL SCIENCE DIVISION INVESTIGATES MECHANISMS OF SCHIZOPHRENIA AND RELATED BRAIN DISORDERS IN CLINICAL STUDIES AND IN BIOLOGICAL MATERIAL FROM CLINICAL SAMPLES SPECIFICALLY ASCERTAINED, EVALUATED AND MANAGED BY INSTITUTE STAFF AND THROUGH COLLABORATIONS WITH JOHNS HOPKINS UNIVERSITY, THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH), UNIVERSITY OF BARI (ITALY), MEDICAL COLLEGE OF VIRGINIA, MORGAN STATE UNIVERSITY AND OTHERS. 16070140 250000 BASIC SCIENCES: THE CREATION OF MODEL SYSTEMS AT THE INSTITUTE TO STUDY PSYCHIATRIC ILLNESS IS THE MAJOR GOAL OF THE BASIC SCIENCES RESEARCH PROGRAM. USING OUR UNIQUE COLLECTION OF HUMAN BRAIN MATERIAL AND INDUCED PLURIPOTENT STEM CELL LINES, WE ARE DEFINING THE MOLECULAR SIGNATURE OF DISEASE RISK. TO PROVIDE THE BASIS FOR THERAPEUTIC INTERVENTION WE ARE DEVELOPING NEW TECHNOLOGIES USING HUMAN STEM CELLS TO IDENTIFY THE FUNCTIONAL CONSEQUENCES OF GENETIC RISK FACTORS. THE GOAL OF THESE STUDIES IS THE IDENTIFICATION OF THERAPEUTIC TARGETS BASED ON THE MECHANISMS OF DISEASE. 5588288 1276306 DRUG DISCOVERY: IMPROVED GENETIC UNDERSTANDING OF DISEASES OF BRAIN DEVELOPMENT IS REVEALING NEW DRUG DISCOVERY OPPORTUNITIES. GUIDED BY GENETICS, THE INSTITUTE'S DRUG DISCOVERY DIVISION IS INVESTIGATING NEW TARGETS FOR PSYCHIATRIC DISEASES, WITH THE GOAL OF VALIDATING INNOVATIVE APPROACHES THAT WILL LEAD TO NOVEL MEDICINES FOR PATIENTS SUFFERING FROM THESE CONDITIONS. THE DRUG DISCOVERY DIVISION MAINTAINS A STATE OF THE ART MEDICINAL CHEMISTRY LABORATORY AND UNIQUE CAPABILITIES IN TARGET VALIDATION. 26304298 1 1 0 1 0 0 0 0 0 0 1 1 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 86 0 1 152 1 0 0 0 0 0 0 0 0 0 0 0 0 X 10 9 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD X ANDREW MASLAN 4432879615 855 N WOLFE ST STE 300 BALTIMORE MD 21205 HERBERT PARDES MD CHAIRMAN OF THE BOARD 1.00 X 0 0 0 STEVEN S SHARFSTEIN MD DIRECTOR 1.00 X 0 0 0 PAUL B ROTHMAN MD DIRECTOR 1.00 X 0 0 0 GEOFFREY SIMON DIRECTOR 1.00 X 0 0 0 MARY RUBIN DIRECTOR 1.00 X 0 0 0 TAMAR MALTZ DIRECTOR 1.00 X 0 0 0 MILTON MALTZ DIRECTOR 1.00 X 0 0 0 ROBERT MUSE DIRECTOR 1.00 X 0 0 0 DANIEL R GETTS DIRECTOR 1.00 X 0 0 0 LANDON S KING DIRECTOR 1.00 X 0 0 0 DANIEL R WEINBERGER CEO & DIRECTOR 40.00 X X 763001 0 26761 THOMAS MICHAEL HYDE CHIEF MEDICAL OFFICER 40.00 X 411393 0 26761 ELAINE JONES CHIEF OPERATING OFFICER 40.00 X 414835 0 10250 ANDREW MASLAN CFO & TREASURER 40.00 X 347452 0 32033 JAMES BARROW ASSOC. DIR. OF DRUG DISCOV 40.00 X 337058 0 32049 JOEL E KLEINMAN ASSOC. DIR. OF CLINICAL SC 40.00 X 397458 0 26761 BRADY MAHER LEAD INVESTIGATOR 40.00 X 213151 0 31106 SHIZHONG HAN LEAD INVESTIGATOR, DATA SC 40.00 X 197004 0 30931 KERI MARTINOWICH LEAD INVESTIGATOR 40.00 X 203954 0 31139 GREGORY CARR LEAD INVESTIGATOR 40.00 X 191487 0 31267 3476793 0 279058 40 0 1 0 ALVIN HATHAWAY 3533 WHITE CHAPEL ROAD BALTIMORE MD 21215 COMMUNITY OUTREACH CONSULTING 132000 RYAN CUMMINS 2026 CEDARMONT DR FRNKLIN TN 37067 COMMUNICATIONS CONSULTING 120000 2 8464406 17634266 15000000 26098672 DRUG DISCOVERY 900099 1276306 1276306 BASIC SCIENCES 900099 250000 250000 CLINICAL SCIENCES 900099 223498 223498 1749804 672185 672185 18480636 50000 18468061 34187 12575 15813 28388 28388 TAX REFUND 900099 324143 324143 LAB SERVICES INCOME 900099 18444 18444 VIVARIUM INCOME 900099 11479 11479 354066 28903115 1749804 0 1054639 2410907 1587920 822987 11689439 10154142 1535297 490805 394308 96497 1486508 1185292 301216 909441 712934 196507 96806 47336 49470 60550 60550 105000 105000 1168564 882135 286429 42544 42544 1235559 1024670 210889 330588 159680 170908 3159671 2468301 691370 264834 209321 55513 62178 36952 25226 1174765 1089014 85751 74419 74419 OTHER LAB EXPENSES 2629777 2486502 143275 GENERAL LAB SUPPLIES 2093345 2093345 LAB SERVICES 1528782 1528199 583 OTHER EXPENSES 297306 244247 53059 137142 137142 31448930 26304298 5144632 0 1818627 1607216 874880 937502 2029964 1733028 522545 579766 25460121 20768464 3199498 4691657 20059283 18259016 2431210 2431210 170203 6417208 31106210 36656603 3329562 2912707 1198822 1160422 1272830 8617809 5801214 12690938 X 24310645 22987039 994351 978626 25304996 23965665 31106210 36656603 -2545815 1376458 -169974 0 X 0 1 X 0 1 1 X JOHN HOPKINS UNIVERSITY BALTIMORE MD RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 105000 0 0 105000 0 PART II-B, LINE 1: LOBBYING COSTS INCURRED WERE RELATED TO GUIDANCE IN PREPARING AND SUBMITTING EARMARK REQUESTS TO CONGRESS, COORDINATING INTRODUCTIONS TO VARIOUS CONGRESSIONAL MEMBERS AND THEIR RESPECTIVE STAFFS, AND FACILITATING DISCUSSIONS WITH GOVERNMENT AGENCIES REGARDING THE INSTITUTE'S RESEARCH WORK. 11306184 9228475 2077709 10529030 8292563 2236467 3624907 3247426 377481 4691657 INVESTMENT IN BIOTURING, INC. 500000 F INVESTMENT IN LATIGO 1931210 F 2431210 RIGHT OF USE ASSETS 6213108 457(B) PLAN ASSET 204100 6417208 OTHER NONCURRENT LIABILITIES 414435 LEASE LIABILITY 8203374 8617809 X 30109599 1376458 1376458 28733141 169974 169974 28903115 31448930 0 31448930 0 31448930 PART X, LINE 2: A TAX POSITION IS RECOGNIZED AS A BENEFIT ONLY IF IT IS "MORE LIKELY THAN NOT" THAT THE TAX POSITION TAKEN WOULD BE SUSTAINED IN A TAX EXAMINATION, PRESUMING THAT A TAX EXAMINATION WILL OCCUR. MANAGEMENT HAS EVALUATED THE INSTITUTE'S TAX POSITIONS AND HAS CONCLUDED THAT THE INSTITUTE HAS TAKEN NO UNCERTAIN TAX POSITIONS. ACCORDINGLY, THE INSTITUTE HAS NOT RECORDED ANY RESERVES, OR RELATED ACCRUALS FOR INTEREST AND PENALTIES FOR UNCERTAIN INCOME TAX POSITIONS AT JUNE 30, 2023 AND 2022. THE INSTITUTE RECOGNIZES INTEREST AND/OR PENALTIES RELATED TO UNCERTAIN TAX POSITIONS, IF ANY, IN INCOME TAX EXPENSE IN THE ACCOMPANYING STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS. THERE ARE CURRENTLY NO AUDITS FOR ANY OPEN TAX PERIODS FROM JUNE 30, 2019 FORWARD. EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 IP LICENSING DRUG DISCOVERY 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PART III ACCOUNTING METHOD: X 0 1 X X 0 0 0 0 0 0 0 0 0 DANIEL R WEINBERGER CEO & DIRECTOR 675444 0 86939 0 618 0 10250 0 16511 0 789762 0 0 0 THOMAS MICHAEL HYDE CHIEF MEDICAL OFFICER 390934 0 19735 0 724 0 10250 0 16511 0 438154 0 0 0 ELAINE JONES CHIEF OPERATING OFFICER 393284 0 3650 0 17901 0 10250 0 0 0 425085 0 0 0 ANDREW MASLAN CFO & TREASURER 344176 0 3000 0 276 0 10250 0 21783 0 379485 0 0 0 JAMES BARROW ASSOC. DIR. OF DRUG DISCOV 291066 0 45716 0 276 0 10250 0 21799 0 369107 0 0 0 JOEL E KLEINMAN ASSOC. DIR. OF CLINICAL SC 377105 0 19735 0 618 0 10250 0 16511 0 424219 0 0 0 BRADY MAHER LEAD INVESTIGATOR 176268 0 36703 0 180 0 9307 0 21799 0 244257 0 0 0 SHIZHONG HAN LEAD INVESTIGATOR, DATA SC 156104 0 40780 0 120 0 9148 0 21783 0 227935 0 0 0 KERI MARTINOWICH LEAD INVESTIGATOR 179525 0 24249 0 180 0 9340 0 21799 0 235093 0 0 0 GREGORY CARR LEAD INVESTIGATOR 148964 0 42403 0 120 0 9468 0 21799 0 222754 0 0 0 PART I, LINE 1A PAYMENTS FOR BUSINESS USE OF PERSONAL RESIDENCE: THE INSTITUTE RENTS AN APARTMENT IN BALTIMORE, MD FOR IT'S COO, ELAINE JONES, WHO COMMUTES WEEKLY FROM CAPE CHARLES, VIRGINIA. A DAILY COMMUTE FROM CAPE CHARLES, VA IS OVER 200 MILES EACH WAY, TOO GREAT OF A DISTANCE TO EXPECT A REASONABLE DAILY COMMUTE. PART I, LINE 1B THE INSTITUTE PROVIDED PERSONAL HOUSING AS PART OF A NEGOTIATED COMPENSATION AND BENEFITS PACKAGE. THE INSTITUTE DID NOT ANTICIPATE REPEATING THIS ARRANGEMENT, AND THEREFORE DID NOT ESTABLISH A POLICY GOVERNING THIS TYPE OF ARRANGEMENT. X 2 15000000 MRKT VALUE OF SECURITIES 0 0 0 PART I, COLUMN (B): FOR THE PURPOSES OF SCHEDULE M, LINE 11, SECURITIES - PARTNERSHIPS, LLC OR TRUST INTERESTS, COLUMN B IS REPORTING TWO INSTANCES OF SECURITIES BEING GIFTED BY A SINGLE CONTRIBUTOR. FORM 990, PART VI, SECTION A, LINE 2 TAMAR AND MILTON MALTZ HAVE A FAMILY RELATIONSHIP. GEOFFREY SIMON AND MARY RUBIN HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B REVIEW OF FORM 990 PROCESS: THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTANT AND REVIEWED IN DRAFT FORM BY MANAGEMENT AND THE ORGANIZATION'S ATTORNEY. IT IS CIRCULATED TO THE BOARD OF DIRECTORS FOR REVIEW VIA EMAIL PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C MONITORING CONFLICT OF INTEREST: THERE ARE TWO CONFLICT OF INTEREST POLICIES. ONE GOVERNS DIRECTORS, TRUSTEES, OFFICERS AND KEY EMPLOYEES. PURSUANT TO THIS POLICY, THE COVERED PERSONS MUST SUBMIT A CONFLICT OF INTEREST DISCLOSURE FORM WHEN THEY JOIN OR ARE APPOINTED AND ANNUALLY THEREAFTER. THE SECOND POLICY PRIMARILY GOVERNS RESEARCHERS. ALL COVERED EMPLOYEES UNDER THIS POLICY ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY UPON COMMENCEMENT OF EMPLOYMENT. COVERED PERSONS UNDER EACH POLICY ARE REQUIRED TO DISCLOSE NEW CONFLICTS OF INTEREST TO MANAGEMENT AS SOON AS THEY ARISE. FORM 990, PART VI, SECTION B, LINE 15 DETERMINING COMPENSATION: THE INSTITUTE PERIODICALLY ENGAGES AN INDEPENDENT COMPENSATION CONSULTING FIRM TO REVIEW COMPENSATION AMOUNTS FOR EMPLOYEES INCLUDING THE CEO AND OTHER OFFICERS OF THE INSTITUTE. THE BOARD AND THE EXECUTIVE TEAM USED THE CONSULTING FIRM'S FINDINGS TO MAKE SURE COMPENSATION WAS REASONABLY FAIR AND COMPETITIVE TO ATTRACT AND RETAIN THE BEST PERSONNEL TO HELP THE INSTITUTE ACHIEVE ITS MISSION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICTS OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.